-
-
-
-
-
-
-
Correction: Ipsen provides update on E.U. Marketing Authorization Application for Bylvay® for cholestatic pruritus in patients with Alagille syndrome
-
-
-
-
-
-
-
Albireo (ALBO) Acquired by Ipsen for $42/sh plus $10 CVR
-
-
-
-
-
-
-
Ipsen to acquire Epizyme, expanding its portfolio in oncology
-
-
-
-
-
-
-
Ipsen Confirms U.S. FDA Accepts New Drug Application for Palovarotene as the First Potential Treatment Worldwide for Fibrodysplasia Ossificans Progressiva (FOP)
-
-
-
-
-
-
-
Ipsen Showcases Commitment to Patient-centric Advances in Oncology With Record Number of Abstracts to Be Presented at ESMO 2020 Virtual Congress
-
-
-
-
-
-
-
Ipsen enters into an option agreement with IRICoR and Université de Montréal for a discovery-stage oncology program
-
-
-
-
-
-
-
IPSEN: Description of the Regulatory Framework of the Share Repurchase Program Proposed by the Board of Directors to Be Approved at the Combined Shareholders’ Meeting on 28 May 2019 (12th resolution
-
1,171,042 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

